DOI: https://dx.doi.org/10.18203/2320-1770.ijrcog20163412
Published: 2016-12-15

Sublingual versus vaginal misoprostol for medical termination of pregnancy: a comparative study

Ayswarya Shanmugam, Seethesh Ghose, Pallavee Parida, Jasmina Begum

Abstract


Background: Medical  abortion  with  a  combination  of  mifepristone  and  a  prostaglandin  analogue, as  an  alternative  to  surgical  abortion  in  early  pregnancy.

Methods: This randomized comparative study was conducted for 60 women with pregnancy up to 20 weeks period of gestation after getting approval from the institutional ethics committee and informed consent from the patient. Patients were divided into 2 groups based on computer generated random number. Patients in one group had received 200mg mifepristone orally and after 24 hours 400 mcg of misoprostol sublingually after admission in to labour ward. Dose was repeated every 6 hours up to maximum of 5 doses. Patients in other group had received 200mg mifepristone orally and after 24 hours 400 mcg of misoprostol vaginally after admission in to labour ward. Dose was repeated every 6 hours up to maximum of 5 doses.

Results: The maternal age distribution, parity and gestational age in the two groups were found to be comparable. Requirement of mean dose of misoprostol in sublingual and vaginal were 1300 mcg, 1253 mcg respectively. The mean induction and abortion interval was 15.31±7.9 and 15.41±7.8 hours in sublingual and vaginal respectively. The complete abortion rate was 80% and 83.3% in sublingual and vaginal groups. The rates of side effects were similar in both groups respectively.

Conclusions: There is no significant difference in efficacy and side effects between sublingual and vaginal route of misoprostol for termination of pregnancy.


Keywords


Mifepristone, Misoprostol, MTP, Sublingual, Vaginal, Dose

Full Text:

PDF

References


Cunningham FG, Halvorson, Lisa M. First trimester abortion. In: Hoffman BL, Schorge JO, Bradshaw KD (editors). Williams Gynaecology 2nd ed, New York, NY: Mc Graw - Hill Companies; 2012:170-97.

Dhillon BS, Chandhiok N, Kambo I, Saxena NC. Induced abortion and concurrent adoption of contraception in rural areas of India. Ind J Med Sci. 2004;58(11):478-84.

Say L, Chou D, Gemmill A, Moller AB. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2(6):e323-33.

Drey EA, Foster DG, Jackson RA, Lee SJ, Cardenas LH, Darney PD, et al. Risk factors associated with presenting for abortions in second trimester. Obstet Gynaecol. 2006;107(1):128-35.

Ngai SW, Chand YM, Tang O, Ho PC. Vaginal misoprostol as medical treatment for first trimester spontaneous miscarriage. Hum Reprod. 2001;16(7):1493-6.

Government of India, The Medical Termination of Pregnancy Act, No 34, 1971. Available at https://www.guttmacher.org/pubs/Abortion-India-Lit-Review.

Jejeebhoy SJ, Kalyanwala S, Mundle S, Tank J, Zavier AJ, Kumar R, et al. Feasibility of expanding the medication abortion provider base in India to include Ayurvedic physicians and nurses. Int Perspect Sex Reprod Health. 2012;38(3):133-42.

Ministry of Health and Family Welfare, Family Welfare Statistics of India, New Delhi: Ministry of Health and Family Welfare; 2011.

Ministry of Health and Family Welfare, Health and Family Welfare Statistics of India 2013, New Delhi: Ministry of Health and Family Welfare, Statistics Division, 2013. Available at https://nrhm-mis.nic.in/PubFWStatistics%202013/Complete%20Book.

Special tabulations of data from department of economic and social affairs, population division, UN, World Population Prospects: The 2012 Revision, DVD, NewYork: UN, 2013. Available at http://esa.un.org/unpd/wpp/Publications/Files/WPP2012_HIGHLIGHTS.

Goyel BK, Singh G. Midtrimester MTP using endocervical PGE2 gel and serial intramuscular carboprost. Med J Armed Forces India. 2000;56:37-9.

Cadepond F, Ulmann A, Baulieu EE. RU 486 (mifepristone) mechanism of action and clinical uses. Ann Rev of Med. 1997;48:129-56.

Zieman M, Fong S, Benowitz NL, Banskter D, Darney PD. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol. 1997;90(1):88-92.

Tang OS, Schweer H, Seyberth HW, Lee SWH, Ho PC. Pharmacokinetics of different routes of administration of misoprostol. Human Reprod. 2002;17:332-6.

Meckstroth KR, Whitaker AK, Bertisch S, Goldberg AB, Darney PD. Misoprostol administered by epithelial routes: drug absorption and uterine response. Obstet Gynecol. 2006;108:582-90.

Tanha FD, Golgachi T, Niroom N, Ghaharzadeh M, Nasr R. Sublingual versus vaginal misoprostol for second trimester termination: a randomized clinical trial. Arch Gynecol Obstet. 2013;287(1):65-9.

Sedgh G, Henshaw SK, Singh S, Bankole A, Drescher J. Legal abortion worldwide: incidence and recent trends. Int fam plan perspect. 2007;33(3):106-16.

Urquhart DR, Templeton AA, Shinewi F, Chapman M, Hawkins K, McGarry J. The efficacy and tolerance of mifepristone and prostaglandin in termination of pregnancy of less than 63 days gestation: UK Multicentre Study-final results. Contraception. 1997;55:1-5.

Divya PR, Neelima NV. Safety and efficacy of using mifepristone and misoprostol combination in termination of first trimester missed abortion - a prospective study. Int J medical and applied science. 2014;(3):14-9.

Gronlund A, Gronlund L, Clevin L, Andersen B, Palmgren N, Lidegaard O, et al. Management of missed abortion, comparison of medical treatment with either mifepristone+misoprostol or misoprostol alone with surgical evacuation. A multi-centre trial in Copenhagen, Denmark. Acta Obstet Gynecol Scand. 2002;81:1060-5.

Ramsey PS, Savage K, Lincoln T, Owen J. Vaginal misoprostol versus concentrated oxytocin and vaginal PGE2 for second trimester labour induction. Obstet Gynecol. 2004;104:138-45.

Kushwah DS, Kushwah B, Salman MT, Verma VK. Acceptability and safety profile of oral and sublingual misoprostol for uterine evacuation following early fetal demise. Indian J Pharmacol. 2011;43(3):306-10.